Contents

Search

neflamapimod

Indication: - investigational agent for treatment of Alzheimer's disease Mechanism of action: - oral inhibitor of the enzyme p38 MAP kinase alpha

General

pharmaceutical agents for treatment of Alzheimer's disease (Alzheimer's agent)

References

  1. Idrus AAI EIP Pharma nabs $20.5M to push Alzheimer's drug through phase 2. FierceBiotech. May 16, 2018 https://www.fiercebiotech.com/biotech/eip-pharma-nabs-20-5m-to-push-alzheimer-s-med-through-phase-2